Table 6.
Association between DSS score, therapy delay and outcome between control + RRT vs. CytoSorb group. Please note that groups containing not enough patients for a reliable statistical evaluation were classified as not applicable (n.a.); therefore, no analysis was performed in these groups. Presented are frequency and percentage (%) and levels of significance.
| ICU Mortality | Hospital Mortality | |||||
|---|---|---|---|---|---|---|
| Control + RRT Group (n = 69) | CytoSorb Group (n = 198) | p-Value | Control + RRT Group (n = 69) | CytoSorb Group (n = 198) | p-Value | |
| DSS <6 points, CytoSorb delay ≤12 h | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
| DSS 6–8 points, CytoSorb delay ≤12 h | 27 (58.7%) | 21 (47.7%) | 0.303 | 30 (65.2%) | 21 (47.7%) | 0.096 |
| DSS >8 points, CytoSorb delay ≤12 h | 12 (92.3%) | 17 (51.5%) | 0.009 * | 12 (92.3%) | 21 (63.6%) | 0.053 |
| DSS <6 points, CytoSorb delay >12–24 h | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
| DSS 6–8 points, CytoSorb delay >12–24 h | 27 (58.7%) | 25 (54.3%) | 0.678 | 30 (65.2%) | 26 (56.5%) | 0.398 |
| DSS >8 points, CytoSorb delay >12–24 h | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
| DSS <6 points, CytoSorb delay >24 h | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
| DSS 6–8 points, CytoSorb delay >24 h | 27 (58.7%) | 19 (70.3%) | 0.318 | 30 (65.2%) | 19 (70.3%) | 0.654 |
| DSS >8 points, CytoSorb delay >24 h | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. |
* = Statistically significant using Bonferroni-adjusted alpha critical value = 0.017.